The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lenalidomide plus low-dose dexamethasone compared with thalidomide plus low-dose dexamethasone in the treatment of newly diagnosed multiple myeloma: Results of an ongoing prospective randomized phase III trial.
A. Mookerjee
Research Funding - Dr. Reddy's Laboratories
A. Sharma
No relevant relationships to disclose
R. Gupta
No relevant relationships to disclose
L. Kumar
Research Funding - Dr. Reddy's Laboratories